Pacira BioSciences, Inc.
$ 24.72
3.60%
17 Apr - close price
- Market Cap 1,063,486,000 USD
- Current Price $ 24.72
- High / Low $ 24.89 / 23.81
- Stock P/E 154.50
- Book Value 16.86
- EPS 0.16
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.01 %
- 52 Week High 27.64
- 52 Week Low 18.80
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Analyst Target Price
$28.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0.57 | 0.7 | -0.11 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 | 0.78 | 0.53 |
| Estimated EPS | 0.9017 | 0.65 | 0.72 | 0.5971 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.88 | 0.78 | 0.76 | 0.62 |
| Surprise | -0.3317 | 0.05 | -0.83 | 0.0229 | 0.0797 | 0.09 | 0.19 | 0 | 0.01 | -0.06 | 0.02 | -0.09 |
| Surprise Percentage | -36.7861% | 7.6923% | -115.2778% | 3.8352% | 9.5989% | 12.8571% | 27.1429% | 0% | 1.1364% | -7.6923% | 2.6316% | -14.5161% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2026-04-17 09:09:10
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it will report its first quarter 2026 financial results after the market close on Thursday, April 30, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results. Interested parties can pre-register for the call or access a live audio webcast on Pacira's investor relations website.
2026-04-16 21:09:43
Pacira BioSciences, Inc. announced it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results, which can be accessed by pre-registering or via their investor relations website. Pacira is a leader in non-opioid pain therapies, including EXPAREL, ZILRETTA, and iovera, and is advancing a pipeline of clinical-stage assets.
2026-04-16 12:10:20
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced it will report its first-quarter 2026 financial results after the U.S. markets close on Thursday, April 30, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET, with a replay available on their website for approximately two weeks. Pacira is an industry leader in non-opioid pain therapies, with several commercial-stage treatments and a developing pipeline.
2026-04-16 12:10:20
Pacira BioSciences (Nasdaq: PCRX) announced it will report its first-quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET following the release, with registration required for telephone participants to receive dial-in information and a PIN. A webcast replay will be available on Pacira's website for approximately two weeks.
2026-04-16 11:39:31
Pacira BioSciences, Inc. announced that it will report its first-quarter 2026 financial results after U.S. markets close on Thursday, April 30, 2026. The company will host a live conference call and webcast at 4:30 p.m. ET following the release, accessible via pre-registration for telephone participants or through the "Events" page on its investor relations website.
2026-04-14 20:10:20
Pacira BioSciences (NASDAQ:PCRX) has received an average "Hold" rating from analysts, with a 12-month average price target of $30.25. Recent insider sales include Jonathan Slonin and Lauren Riker reducing their stakes. The company missed its latest quarterly earnings and revenue estimates, reporting EPS of $0.57 against a consensus of $0.85 and revenue of $196.87M against $201.93M.
